Three reports have described DITMA caused by pentostatin, a purine analog used in lymphoproliferative diseases (29). It is important to exclude any other diagnosis before attributing TMA to a drug. During the last decade, laboratory criteria have been added to support the causal relationship between a drug and TMA (2). The hypothesis is based on the observation of the timing of TMA occurrence, the pattern of disease, the exclusion of a better explanation thorough investigation. There are currently no prospective studies supporting the efficacy of these treatments in DITMA.

Associated Data
Immune-mediated drug-induced TMA is due to an antibody (Ab) formation against a drug or its metabolite. Such patients have high rates of progression to kidney failure and disease recurrence after transplantation. Genetic testing is recommended in all patients with recurrent episodes of hypertensive emergency, TMA, and progressive kidney disease. However, there is growing evidence that complement activation is the underlying disorder behind the majority of malignant hypertension cases, particularly in young patients.

From Guidelines To Practice: The Pharmacist’s Role In Chronic Heart Failure Therapy Optimization
Immune-mediated reactions - Just like DITP, drugs can cause TMA by the formation of drug-dependent antibodies. We believe that greater awareness of drug-induced TMA together with the methods for diagnosis described in this report can provide support for clinicians who evaluate patients with suspected TMA. Some drugs, such as gemcitabine,(22) may cause TMA by both immune-mediated and dose-dependent toxicity-mediated mechanisms. One published report of gemcitabine-mediated TMA described the clinical features of an acute, immune-mediated mechanism;(22) the other 5 patients had the clinical features of a chronic, dose-dependent toxic mechanism. Excluded from the published reports are 12 patients reported from the Oklahoma Registry(8) and 9 reported patients from the BloodCenter of Wisconsin(9) with quinine-induced TMA and one patient reported from the Oklahoma Registry with pentostatin-induced TMA.(7)

HIT (heparin-induced Thrombocytopenia)
This would explain why different individuals, even under the same circumstances, may show a wide range of different clinical evolutions 92,93,109. These probably would not be significant in normal circumstances but may lead to complement activation under the extremely stressful situation of HSCT. Additionally, significantly higher CH50 levels were described in HSCT-TMA patients 104,120. Measurement of complement molecules and functional assays (for example, CH50 for the classical pathway, AP50 for the alternative pathway) allow recognition of the overactivated pathway 93,118.
Based on this experience, we have changed our requirement for assigning patients to the drug-induced category in the Oklahoma Registry. In contrast, the typical pathologic features of TMA can be caused by dose-dependent toxic adverse drug reactions, as well as by immune-mediated reactions, and these patients are included in descriptions of DITMA. There have been many reports attributing TMA to many different drugs; most reports have been repeated descriptions of previously reported drugs.(3) This suggests a bias that more frequently reported drugs are the most likely suspects when a diagnosis of DITMA is considered.
Cancer Drug-induced TMA
Renal and colonic endothelial cell injury is responsible for most of the symptoms, but the central nervous system, pancreas, and other organs can be affected, and this dictates the extent and outcome of STEC HUS. Shiga toxin is absorbed into the circulation bound to globotriaosylceramide-3 (Gb3) and translocated into microvascular endothelial cells and other tissues expressing the receptor. Most are also involved in clinical and/or basic science research in this area, and all are involved in lecturing on related topics at the University, national or international level. All are clinicians involved in treating pediatric or adult patients presenting with TMA. The focus of this article is not to discuss the detailed pathophysiology or etiologies of these conditions or their treatments.
IL-23 Inhibitors In Psoriasis: Optimizing Access And Patient Outcomes Across Integrated Systems
Complement blockers may be helpful in select cases, and trials in this disease space are ongoing. CM-TMA can be triggered by high risk events late in pregnancy or especially in the postpartum period, and complement gene variants can be found in approximately half of these cases. TTP is diagnosed by ADAMTS13 deficiency and responds to plasma exchange (congenital TTP) or immunosuppression (immune-mediated TTP). Preeclampsia results from abnormal placentation with production of anti-angiogenic (i.e., anti-VEGF) factors triggering complement activation.
Fromm L. Suspected hydroxychloroquine-induced thrombotic thrombocytopaenic purpura. Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome. Shrestha A, Khosla P, Wei Y. Docetaxel-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer?
Advancing Multiple Sclerosis Treatment: Exploring Evolving Therapies And Patient-Centered Approaches
- Although the list of drugs potentially involved as causative for TMA are rapidly increasing, the scientific literature on DITMA is quite scarce, especially if compared to surveys on primary TMAs e.g., atypical hemolytic-uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), which are deemed to be rarer clinical entities.
- Computational prediction algorithms are used to predict the potential impact of these “variants of uncertain clinical significance” (VUS) on the mature protein.
- Many drugs have been reported to cause thrombotic microangiopathy (TMA), often described as thrombotic thrombocytopenic purpura (TTP) or hemolytic-uremic syndrome (HUS).
- In some, treatment with eculizumab was successful (50).
- Defibrotide is an antiplatelet agent that reduces endothelial cell activation and increases endothelial cell-mediated fibrinolysis.
Acquired cobalamin deficiency-induced pseudo-TMA from pernicious anemia or malabsorption is as easily missed as it is treated. After kidney transplantation, 25%–50% of CM-TMA will recur. The mortality rate of cancer-related TMA is high due to its association with disseminated malignancies or withdrawal of chemotherapy. The role of eculizumab requires further randomized controlled trials. Genetic testing for complement proteins is reserved for severe cases. Pathogenesis of Strep pneumo-HUS is attributed to pneumococcal neuraminidase, which cleaves sialic acid residues exposing a cell surface component called T-antigen and initiating complement activation.
This disease, now known as thrombotic thrombocytopenic purpura (TTP), is one of the most extensively studied subtypes of TMA. The first case of TMA was reported in 1924 by Moschcowitz who described a 16-year-old girl with acute paralysis, fever, petechial rash, MAHA, severe thrombocytopenia, and kidney dysfunction, culminating in neurologic deficits, coma, and death within days.1 Autopsy revealed widespread hyaline thrombi in kidney and heart capillaries. Chemotherapy offers curative treatment for early stage cancer and palliation for late-stage cancer but may have off-target effects including kidney toxicity. Biopsy revealed chronic thrombotic microangiopathy (TMA), acute tubular injury, and 10% interstitial fibrosis and tubular atrophy.

Epidemiology Of Cancer-Associated TMA

Failure to recognize a drug as the cause of TMA, especially immune-mediated TMA, may have critical consequences if the patient is reexposed to the drug. TMA resulting from quinine may involve immune injury to endothelial cells.10 Better understanding of the mechanisms of DITMA should provide a basis for better diagnosis and treatment. TMA resulting from inhibitors of vascular endothelial growth factors8,9 has been established to involve injury to renal podocytes.
3 Infection Associated TMAs
Tests for drug-dependent antibodies reactive with platelets and neutrophils were performed by the BloodCenter of Wisconsin.(5) For Oklahoma Registry patients, tests for drug-dependent antibodies were performed on serum from patients with suspected dose-dependent toxic reactions as well as suspected immune-mediated reactions, since the distinction between these two categories of adverse drug reactions may not always be clear. These patients are not in our cohort of consecutive patients; none were suspected to have a drug-induced etiology; all had acquired TTP with severe ADAMTS13 deficiency. For this study we included all patients enrolled through 2014 with their first episode of clinically suspected acquired TTP (475 patients) and also all patients in whom TMA was first identified by a kidney biopsy (12 patients).

Complement‐mediated aHUS can develop throughout life but there is an age‐related penetrance with the likelihood of disease development increasing in those who have more than one complement mutation. The genetic variants reported in complement‐mediated aHUS are not causative but are predisposing with penetrance low. There is not a rapid screening test for complement‐mediated disease and it is initially a diagnosis of exclusion with genetic and autoimmune analysis subsequently confirming the diagnosis.
Six months before presentation, disease progression prompted treatment change to bevacizumab/gemcitabine, although one month ago, bevacizumab was discontinued due to new-onset difficult-to-control hypertension. During the active phase of the disease kidney failure can often be severe enough to require manual blood cleaning with dialysis. In many of the more atypical TTP/HUS disease patterns the optimal treatment has not yet been standardized. The toxin makes its way into the blood stream and then damages endothelial cells in the kidney. When the endothelial cells of capillaries become damaged, blood flow through the kidney slows (Figure 2).